Protagonist Therapeutics (PTGX) Short term Debt (2018 - 2023)

Protagonist Therapeutics (PTGX) has 6 years of Short term Debt data on file, last reported at $10000.0 in Q2 2023.

• For the quarter ending Q2 2023, Short term Debt fell 87.5% year-over-year to $10000.0; the trailing twelve-month figure through Jun 2023 stood at $10000.0 (down 87.5% YoY), and the FY2022 full-year result was $69000.0, down 92.32% from the prior year.
• Short term Debt fell to $10000.0 in Q2 2023, from $22000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $11.4 million in Q2 2021 to a low of $10000.0 in Q2 2023.
• A 5-year average of $1.8 million and a median of $1.0 million in 2019 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt jumped 1036.19% in 2021 and slumped 99.3% in 2022, its largest moves.
• Tracing PTGX's Short term Debt over 5 years: stood at $1.3 million in 2019, then jumped by 116.48% to $2.7 million in 2020, then slumped by 67.09% to $899000.0 in 2021, then tumbled by 92.32% to $69000.0 in 2022, then sank by 85.51% to $10000.0 in 2023.
• Business Quant data shows PTGX's Short term Debt at $10000.0 in Q2 2023, $22000.0 in Q1 2023, and $69000.0 in Q4 2022.